Leerink Partnrs Has Bearish Estimate for Geron Q2 Earnings

Geron Co. (NASDAQ:GERN - Free Report) - Equities researchers at Leerink Partnrs lowered their Q2 2025 earnings estimates for shares of Geron in a research note issued on Monday, January 6th. Leerink Partnrs analyst F. Khurshid now anticipates that the biopharmaceutical company will earn $0.00 per share for the quarter, down from their prior forecast of $0.01. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Geron's current full-year earnings is ($0.25) per share. Leerink Partnrs also issued estimates for Geron's Q3 2025 earnings at $0.01 EPS and Q4 2025 earnings at $0.02 EPS.

GERN has been the topic of a number of other research reports. HC Wainwright reissued a "buy" rating and set a $9.00 target price on shares of Geron in a research report on Tuesday, December 10th. Needham & Company LLC reissued a "buy" rating and set a $6.00 price objective on shares of Geron in a report on Friday, December 13th. Leerink Partners assumed coverage on Geron in a report on Monday, September 9th. They set an "outperform" rating and a $7.00 target price for the company. Scotiabank began coverage on Geron in a report on Wednesday, October 16th. They issued a "sector outperform" rating and a $6.00 price target on the stock. Finally, Barclays raised Geron to a "strong-buy" rating in a research report on Friday, November 29th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $7.15.

Geron Stock Down 0.9 %

Shares of GERN stock traded down $0.03 on Tuesday, hitting $3.40. The stock had a trading volume of 7,210,068 shares, compared to its average volume of 13,307,387. Geron has a one year low of $1.64 and a one year high of $5.34. The business has a 50 day moving average price of $3.87 and a 200 day moving average price of $4.26. The company has a market cap of $2.06 billion, a PE ratio of -10.63 and a beta of 0.55. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04.

Geron (NASDAQ:GERN - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.05. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The company had revenue of $28.27 million for the quarter, compared to the consensus estimate of $18.97 million. During the same period last year, the business posted ($0.08) EPS. Geron's quarterly revenue was up 17138.4% on a year-over-year basis.

Hedge Funds Weigh In On Geron

Hedge funds have recently modified their holdings of the stock. RTW Investments LP purchased a new stake in Geron during the 3rd quarter worth approximately $200,268,000. Darwin Global Management Ltd. acquired a new stake in shares of Geron during the second quarter worth $106,185,000. Holocene Advisors LP purchased a new stake in shares of Geron during the third quarter valued at $82,498,000. Janus Henderson Group PLC increased its position in shares of Geron by 140.0% in the 3rd quarter. Janus Henderson Group PLC now owns 22,565,846 shares of the biopharmaceutical company's stock valued at $102,193,000 after acquiring an additional 13,163,889 shares during the period. Finally, Farallon Capital Management LLC raised its stake in Geron by 124.6% in the 2nd quarter. Farallon Capital Management LLC now owns 16,837,000 shares of the biopharmaceutical company's stock worth $71,389,000 after acquiring an additional 9,342,000 shares during the last quarter. Institutional investors and hedge funds own 73.71% of the company's stock.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.